- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Strathspey Crown acquires Evolus
Strathspey Crown Holdings has acquired Evolus, which will allow Strathspey Crown’s wholly-owned subsidiary, Alphaeon Corporation, the exclusive license to market the botulinum toxin type A product Evosyal.
Strathspey Crown Holdings has acquired Evolus, which will allow Strathspey Crown’s wholly-owned subsidiary, Alphaeon Corporation, the exclusive license to market the botulinum toxin type A product Evosyal.
Evosyal is developed by Seoul, South Korea manufacturer Daewoong. The product has a 900 kDa neurotoxin molecular complex with a high purity, according to a news release.
Alphaeon launched in July 2013 and the following month it acquired the exclusive U.S. license to Teoxane Laboratories’ full portfolio of hyaluronic acid-based dermal fillers and other cosmetic products marketed as Teosyal.
Evosyal and Teosyal will be marketed pending approval by the Food and Drug Administration. Teosyal is already used widely as a dermal filler in Europe.
